This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

5W Public Relations Adds Cold-EEZE® To Its Consumer Brands Client Roster

NEW YORK, April 13, 2011 /PRNewswire/ -- 5W Public Relations, one of the 25 largest PR Agencies in the U.S., today announced the addition of Cold-EEZE to its diverse roster of consumer clients. Cold-EEZE is clinically proven to reduce the duration and symptoms of the common cold including cough, stuffy nose, sore throat, sneezing, post-nasal drip and hoarseness.

"5WPR is extremely excited to be named PR Agency of Record for Cold-EEZE," said Ronn Torossian, CEO of 5W Public Relations. "We have seen tremendous growth in our consumer wellness division in the last few years and look forward to creating added awareness and excitement to the Cold-EEZE brand."

Cold-EEZE is the No. 1 pharmacist-recommended zinc cold remedy and the proprietary (zinc gluconate) formula is believed by researchers to interfere with the cold virus' ability to reproduce. Cold-EEZE uses natural flavors and has no preservatives or colors. It is non-drowsy, non-agitating and does not affect blood pressure. It actually shortens your cold to help you get well sooner.

5W Public Relations will execute a comprehensive integrated public relations program to promote Cold-EEZE in the consumer marketplace. Key elements will include media relations, celebrity integrations, co-branded partnerships, special events and more.

ABOUT 5W PUBLIC RELATIONS

5W Public Relations ( www.5wpr.com) is a full-service public relations agency known for implementing cutting-edge, customized campaigns designed to drive our clients' business goals and objectives. 5WPR was founded by Ronn Torossian in 2003, and the energetic and focused culture earned the PR firm a spot on the INC. 500 list and recognition as the nation's "fastest-growing PR agency" three years in a row. Our 24/7 approach led the industry's foremost trade magazine to describe 5WPR as "aggressive in a way that clearly resonates with clients looking for a firm staffed with Type A-plus personalities, a BS-free approach, and results from Day One."

About ProPhase Labs

ProPhase Labs (NASDAQ: PRPH) is a diversified natural health medical science company. It is a leading marketer and manufacturer of the Cold-EEZE® family of lozenges and sugar free tablets clinically proven to significantly reduce the severity and duration of the common cold. Cold-EEZE customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. ProPhase Labs has several wholly owned subsidiaries including a manufacturing unit, which consists of an FDA approved facility to manufacture Cold-EEZE lozenges and fulfill other contract manufacturing opportunities. ProPhase also owns 50% of Phusion Laboratories, LLC ("Phusion"). Phusion licenses a revolutionary proprietary technology that has the potential to improve the delivery and/or efficacy of many active ingredients or compounds. The joint venture plans to formulate and test products to exploit market opportunities within ProPhase's robust OTC distribution channels. For more information, visit www.ProPhaseLabs.com.

CONTACT:  Ronn Torossian, +1-212-999-5585, ronn@5wpr.com

SOURCE 5W Public Relations

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs